Paceport Swan-Ganz Data Collection Study

Sponsor
Montreal Heart Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT04782154
Collaborator
Edwards Lifesciences (Industry)
500
1
6.7
74.6

Study Details

Study Description

Brief Summary

RV dysfunction has been associated with increased mortality in the ICU and cardiac surgical patients. Thus, early identification of RV dysfunction at less severe stages will allow for earlier intervention and potentially better patient outcomes. However, so far, no studies have reported prospectively the prevalence of abnormal RV pressure waveform during cardiac surgery and in the ICU. Our primary hypothesis is that the prevalence of abnormal RV pressure waveform occurs in more than 50% of cardiac surgical patients throughout their hospitalization. Those patients with abnormal RV pressure waveform will be more prone to post-operative complications related to RV dysfunction and failure in the OR and ICU.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The pulmonary artery catheter (PAC) consists of an intravenous device placed in the pulmonary artery to measure cardiac output, pulmonary artery pressures (Richard C, 2011) as well as cardiac filling pressures. Since its initial presentation by Swan in 1970 (H J Swan, 1970), several modifications were made on the initial catheter now allowing continuous assessment of cardiac output, continuous monitoring of stroke volume (SV), systemic vascular resistance (SVR) and mixed venous saturation (SvO2) (Arora, 2014) (H J Swan, 1970) (Richard C, 2011). We intend to enhance current Swan-Ganz catheters with clinical decision support tools to early identify hemodynamically unstable states that can lead to further deterioration of the patient's health state.

    Right ventricular (RV) dysfunction is mostly associated to a decrease in contractility, right ventricular pressure overload or right ventricular volume overload (François Haddad, 2008). RV dysfunction can occur in several clinical scenarios in the intensive care unit (ICU) and operating room (OR): pulmonary embolism, acute respiratory distress syndrome (ARDS), septic shock, RV infarction, and in pulmonary hypertensive patients undergoing cardiac surgery (François Haddad, 2008). RV dysfunction has been associated with increased mortality in the ICU and cardiac surgical patients (André Y. Denault, 2006) (Denault AY B. J.-S., 2016). Thus, early identification of RV dysfunction at less severe stages will allow for earlier intervention and potentially better patient outcomes. Unfortunately, identifying which patients will develop RV dysfunction and then progress towards RV failure have proven difficult. One of the reasons for delaying the diagnosis of RV dysfunction could be the lack of uniform definition, especially in the perioperative period. Echocardiographic definitions of RV dysfunction have been described in previous studies: RV fractional area change (RVFAC) < 35 %, tricuspid annular plane systolic excursion (TAPSE) < 16 mm, tissue Doppler S wave velocity <10 cm/s, RV ejection fraction (RVEF) <45% and RV dilation have been related to RV dysfunction (Rudski LG, 2010). However, these echocardiographic indices cannot be continuously monitored and are insufficient in describing RV function. The diagnosis of fulminant RV failure is more easily recognized as a combination of echocardiographic measures, compromised hemodynamic measures and clinical presentation (Raymond M, 2019) (François Haddad, 2008) (Haddad F, 2009). RV dysfunction is inevitably associated with absolute or relative pulmonary hypertension because of the anatomic and physiological connection between the RV and pulmonary vascular system (Naeije R, 2014) (François Haddad, 2008). The gold standard for measuring pulmonary pressure is still the pulmonary artery catheter. However, RV output can initially be preserved despite of pulmonary hypertension (Denault AY C. M., 2006). It is therefore mandatory that early, objective, continuous, easily obtainable and subclinical indices of RV dysfunction are found and validated to initiate early treatment of this disease.

    Since 2002, Dr Denault's group at Montreal Heart Institute has been using continuous RV pressure waveform monitoring initially for the diagnosis of RV outflow tract obstruction (Denault A, 2014) and then for RV diastolic dysfunction evaluation (St-Pierre P, 2014) (Myriam Amsallem, 2016). Preliminary data based on a retrospective study on 259 patients found that 110 (42.5%) patients had abnormal RV gradients before cardiopulmonary bypass (CPB).Abnormal RV diastolic pressure gradient was associated with higher EuroSCORE II (2.29 [1.10-4.78] vs. 1.62 [1.10-3.04], p=0.041), higher incidence of RV diastolic dysfunction using echocardiography (45 % vs. 29 %, p=0.038), higher body mass index (BMI) (27.0 [24.9-30.5] vs. 28.9 [25.5-32.5], p=0.022), pulmonary hypertension (mean pulmonary artery pressure (MPAP) > 25 mmHg) (37 % vs. 48 %, p=0.005) and lower pulmonary artery pulsatility index (PAPi) (1.59 [1.19-2.09] vs. 1.18 [0.92-1.54], p<0.0001). Patients with abnormal RV gradient had more frequent difficult separation from CPB (32 % vs. 19 %, p=0.033) and more often received inhaled pulmonary vasodilator treatment before CPB (50 % vs. 74 %, p<0.001). However, this was retrospective and limited to the pre-CPB period.

    In 2017, in a review article on RV failure in the ICU (Hrymak C, 2017), RV pressure waveform monitoring using the paceport of the pulmonary artery catheter was recommended as a simple method of monitoring RV function (Rubenfeld GD, 1999). However, no studies have reported prospectively the prevalence of abnormal RV pressure waveform during cardiac surgery and in the ICU.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Paceport Swan-Ganz Data Collection Study
    Actual Study Start Date :
    Aug 9, 2021
    Anticipated Primary Completion Date :
    Mar 1, 2022
    Anticipated Study Completion Date :
    Mar 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Proportion of abnormal diastolic RV waveforms before CPB, after CPB and in the ICU [From thermodilution catheter insertion until 2 hours after ICU arrival]

      Abnormal RV pressure waveform will be defined as a difference between the RV end-diastolic minus the early-diastolic pressure > 4 mmHg and a RVdP/dt < 400 mmHg.

    Secondary Outcome Measures

    1. Proportion of patients with difficult and complex separation from cardiopulmonary bypass at the end of cardiac surgery [From the discontinuation of cardiopulmonary bypass until ICU arrival after surgery, assessed up to 4 hours]

      Difficult separation from cardiopulmonary bypass: instability requiring at least two different types of pharmacological agents (i.e., inotropes ± vasopressors ± inhaled agents) Complex separation from cardiopulmonary bypass: Hemodynamic instability requiring return on cardiopulmonary bypass or addition of mechanical support (intra-aortic balloon pump or extra-corporeal membrane oxygenator)

    2. Cumulative time of Persistent Organ Dysfunction or Death (TPOD) during the first 28 days after cardiac surgery [Up to 28 days or until hospital discharge]

      TPOD is a continuous variable representative of the burden of care and morbidity during the first 28 days following cardiac surgery and was chosen to circumvent issues arising for using other clinical endpoint such as ICU length of stay

    3. Incidence of deaths during hospitalisation [Up to 28 days or until hospital discharge]

      Death from any cause

    4. Incidence of acute kidney injury (AKI) [Up to 28 days or until hospital discharge]

      Acute kidney injury (AKI) according to KDIGO serum creatinine criteria: Stage 1: ≥50% or 27 umol/L increases in serum creatinine, Stage 2: ≥100% increase in serum creatinine, Stage 3 ≥200% increase in serum creatinine or an increase to a level of ≥254 umol/L or dialysis initiation.

    5. Incidence of major bleeding [Up to 28 days or until hospital discharge]

      Major bleeding is defined by the Bleeding Academic Research Consortium (BARC) as one of the following: • Perioperative intracranial bleeding within 48h • Reoperation after closure of sternotomy for the purpose of controlling bleeding • Transfusion of ≥5 units of whole blood of packed red blood cells within a 48 hours period • Chest tube output ≥2L within a 24 hours period

    6. Incidence of surgical reintervention for any reasons [Up to 28 days or until hospital discharge]

      Re-operation after the initial surgery for any cause

    7. Incidence of deep sternal wound infection or mediastinitis [Up to 28 days or until hospital discharge]

      Diagnosis of a deep incisional surgical site infection or mediastinitis by a surgeon or attending physician

    8. Incidence of delirium [Up to 28 days or until hospital discharge]

      Delirium is defined as an intensive care delirium screening checklist (ICDSC) score(18) of ≥4 in the week following surgery or positive result for the Confusion Assessment Method for the ICU (CAM-ICU).

    9. Incidence of stroke [Up to 28 days or until hospital discharge]

      Central neurologic deficit persisting longer than 72 hours

    10. Total duration of ICU stay in hours [Up to 28 days or until hospital discharg]

      Number of hours passed in the ICU

    11. Duration of vasopressor requirements (in hours) [Up to 28 days or until hospital discharge]

      Vasopressors include norepinephrine, epinephrine, dobutamine, vasopressin, phenylephrine, milrinone, isoproterenol and dopamine

    12. Up to 28 days or until hospital discharge [Up to 28 days or until hospital discharge]

      Number of days hospitalized from the day of surgery to discharge

    13. Duration of mechanical ventilation (in hours) [Up to 28 days or until hospital discharge]

      A duration of >24 hours will be considered prolonged ventilation requirements.

    14. Incidence of major morbidity or mortality [Up to 28 days or until hospital discharge]

      Including death, prolonged ventilation, stroke, renal failure (Stage ≥2), deep sternal wound infection and reoperation for any reason.

    15. Right ventricular ejection fraction [From arrival to the operating room until 2 hours after ICU arrival]

      Assessed by the American Society of Echocardiography guidelines

    16. Right ventricular fractional area change [From arrival to the operating room until 2 hours after ICU arrival]

      Assessed by the American Society of Echocardiography guidelines

    17. Right ventricular strain [From arrival to the operating room until 2 hours after ICU arrival]

      Assessed by the American Society of Echocardiography guidelines

    18. Tricuspid annular plane systolic excursion [From arrival to the operating room until 2 hours after ICU arrival]

      Assessed by the American Society of Echocardiography guidelines

    19. Right ventricular performance index [From arrival to the operating room until 2 hours after ICU arrival]

      Assessed by the American Society of Echocardiography guidelines

    20. Portal flow pulsatility fraction [From arrival to the operating room until 2 hours after ICU arrival]

      Portal flow pulsatility fraction

    21. Right ventricular stroke work index [From arrival to the operating room until 2 hours after ICU arrival]

      0.0136x Stroke volume index x (Mean pulmonary artery pressure-mean right atrial pressure)

    22. Relative pulmonary pressure [From arrival to the operating room until 2 hours after ICU arrival]

      The ratio of the mean systemic arterial pressure divided by the mean pulmonary artery pressure

    23. Right ventricular function index [From arrival to the operating room until 2 hours after ICU arrival]

      Defined as (isovolumic contraction time + isovolumic relaxation time)/RV ejection time

    24. Pulmonary artery pulsatility index (PAPi) [From arrival to the operating room until 2 hours after ICU arrival]

      Defined as (systolic pulmonary artery pressure - diastolic pulmonary artery pressure)/central venous pressure

    25. Compliance of the pulmonary artery (CPA) [From arrival to the operating room until 2 hours after ICU arrival]

      Stroke volume divided by the pulmonary artery pulse pressure (systolic minus the diastolic pulmonary artery pressure)

    26. Pulsatility of femoral venous flow [From arrival to the operating room until 2 hours after ICU arrival]

      Velocity variations of blood flow in the femoral vein during the cardiac cycle

    27. Right ventricular outflow tract obstruction [From arrival to the operating room until 2 hours after ICU arrival]

      Right Ventricular Systolic pressure minus Pulmonary Artery Systolic pressure ≤ 6 mmHg.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Be ≥ 18 years of age

    • Participate in the Informed Consent process and sign/date the approved informed consent forms

    • Projected to receive Swan-Ganz catheter as part of procedure/standard of care with intermittent cardiac output and mixed venous oxygen saturation (SvO2) measures

    Exclusion Criteria:
    • Refuse to sign consent

    • Have left bundle branch block

    • Have recurrent sepsis

    • Have hypercoagulopathy

    • Allergic to FORE-SIGHT Elite sensor adhesive

    • Latex allergy due to presence of latex in the Swan-Ganz catheter balloon.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Montreal Heart Institute Montreal Quebec Canada H1T 1C8

    Sponsors and Collaborators

    • Montreal Heart Institute
    • Edwards Lifesciences

    Investigators

    • Principal Investigator: Andre Y Denault, MD,PhD, Montreal Heart Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Andre Denault, MD, PhD, FRCPC, ABIM-CC, Montreal Heart Institute
    ClinicalTrials.gov Identifier:
    NCT04782154
    Other Study ID Numbers:
    • 2018-20
    First Posted:
    Mar 4, 2021
    Last Update Posted:
    Sep 5, 2021
    Last Verified:
    Aug 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Andre Denault, MD, PhD, FRCPC, ABIM-CC, Montreal Heart Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 5, 2021